NetworkNewsBreaks – Vivos Therapeutics Inc. (NAS
Post# of 51
(Total Views: 208)
Posted On: 08/26/2021 4:16:42 PM
NetworkNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Partners with Empower Sleep in Effort to Improve OSA Diagnosis, Treatment
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), is teaming up with Empower Sleep. Vivos and the California-based company, which works to empowering patients with affordable, accessible and personalized telemedicine sleep care, are partnering to offer key diagnostic and medical consultation services to people across North America who suffer from OSA. The partnership will combine core technologies from each company to develop an accessible platform for patients being screened for OSA; the solution will be available throughout North America and will provide personalized insights for those patients. The end goal is to assist patients in identifying the impact that sleep can have on overall health and help them to receive appropriate treatment for sleep-disordered breathing disorders, including mild to moderate OSA. The solution leverages Vivos’ VivoScore product, which is a biometric ring recording device that enables users to take a simple, comfortable sleep test in the privacy of their own homes. Qualified Empower Sleep personnel will then interpret the test results, which automatically uploaded. Finally, recommended treatments and follow-up visits are then provided. “Our trained providers’ VivoScore sleep test use has increased by more than 300% from just a few weeks ago,” said Vivos chair and CEO Kirk Huntsman in the press release. “What’s more, about half of those patients are testing positive for OSA. Simply put, VivoScore is gaining traction, and we believe that this new cooperative relationship with Empower Sleep will add a vital medical diagnostic and consultative component to our patient-friendly sleep apnea treatment ecosystem. We believe that more screenings and confirmed diagnoses of OSA mean that more patients will seek what is often lifesaving treatment for their OSA, which may include using the Vivos System.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), is teaming up with Empower Sleep. Vivos and the California-based company, which works to empowering patients with affordable, accessible and personalized telemedicine sleep care, are partnering to offer key diagnostic and medical consultation services to people across North America who suffer from OSA. The partnership will combine core technologies from each company to develop an accessible platform for patients being screened for OSA; the solution will be available throughout North America and will provide personalized insights for those patients. The end goal is to assist patients in identifying the impact that sleep can have on overall health and help them to receive appropriate treatment for sleep-disordered breathing disorders, including mild to moderate OSA. The solution leverages Vivos’ VivoScore product, which is a biometric ring recording device that enables users to take a simple, comfortable sleep test in the privacy of their own homes. Qualified Empower Sleep personnel will then interpret the test results, which automatically uploaded. Finally, recommended treatments and follow-up visits are then provided. “Our trained providers’ VivoScore sleep test use has increased by more than 300% from just a few weeks ago,” said Vivos chair and CEO Kirk Huntsman in the press release. “What’s more, about half of those patients are testing positive for OSA. Simply put, VivoScore is gaining traction, and we believe that this new cooperative relationship with Empower Sleep will add a vital medical diagnostic and consultative component to our patient-friendly sleep apnea treatment ecosystem. We believe that more screenings and confirmed diagnoses of OSA mean that more patients will seek what is often lifesaving treatment for their OSA, which may include using the Vivos System.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)